Bruno MA, Vanhaudenhuyse A, Thibaut A, Moonen G, Laureys S From unresponsive wakefulness to minimally conscious PLUS and functional locked-in syndromes: recent advances in our understanding of disorders of consciousness. J Neurol. 2011 Jul;258(7):1373-84. doi: 10.1007/s00415-011-6114-x. Epub 2011 Jun 16.
Fernandez-Espejo D, Owen AM Detecting awareness after severe brain injury. Nat Rev Neurosci. 2013 Nov;14(11):801-9. doi: 10.1038/nrn3608. Epub 2013 Oct 3.
Gerrard P, Zafonte R, Giacino JT Coma Recovery Scale-Revised: evidentiary support for hierarchical grading of level of consciousness. Arch Phys Med Rehabil. 2014 Dec;95(12):2335-41. doi: 10.1016/j.apmr.2014.06.018. Epub 2014 Jul 7.
Giacino JT, Fins JJ, Laureys S, Schiff ND Disorders of consciousness after acquired brain injury: the state of the science. Nat Rev Neurol. 2014 Feb;10(2):99-114. doi: 10.1038/nrneurol.2013.279. Epub 2014 Jan 28.
Giacino JT, Kalmar K, Whyte J The JFK Coma Recovery Scale-Revised: measurement characteristics and diagnostic utility. Arch Phys Med Rehabil. 2004 Dec;85(12):2020-9. doi: 10.1016/j.apmr.2004.02.033.
Liberati G, Hunefeldt T, Olivetti Belardinelli M Questioning the dichotomy between vegetative state and minimally conscious state: a review of the statistical evidence. Front Hum Neurosci. 2014 Nov 3;8:865. doi: 10.3389/fnhum.2014.00865. eCollection 2014.
Posner J, Plum F, Saper C Plum and Posner's Diagnosis of Stupor and Coma. New York, NY: Oxford University Press.; 2007
Raichle ME The restless brain. Brain Connect. 2011;1(1):3-12. doi: 10.1089/brain.2011.0019.
Rohaut B, Faugeras F NL Neurology of consciousness impairments. In: Stevens RD, Sharshar T, Ely EW (eds.). Brain Disorders in Critical Illness. New York, NY: Cambridge University Press. Vol ; 2013:59-67
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
